Amy Rhoden Smith
About Amy Rhoden Smith
Amy Rhoden Smith is a Gene Therapy Development Leader at Precision BioSciences, Inc., with extensive experience in bio-organic chemistry and gene editing technologies. She has held various scientific roles at notable organizations, including Moderna Therapeutics and Intellia Therapeutics, and has a strong academic background in chemistry and organic chemistry.
Work at Precision BioSciences
Amy Rhoden Smith has served as the Gene Therapy Development Leader at Precision BioSciences, Inc. since 2018. In this role, she focuses on advancing gene therapy initiatives, utilizing her expertise in bio-organic chemistry and mRNA technology. Her leadership in this position involves guiding cross-functional teams to drive projects from conception to execution, ensuring the successful development of innovative therapeutic solutions.
Education and Expertise
Amy Rhoden Smith earned her Bachelor of Science (BS) in Chemistry from the College of Charleston, where she studied from 2004 to 2008. She furthered her education at The University of Texas at Austin, obtaining a Doctor of Philosophy (Ph.D.) in Organic Chemistry from 2008 to 2013. Her academic background provides a strong foundation for her specialization in bio-organic chemistry, particularly in mRNA, CRISPR-Cas9 gene editing, and oligonucleotide therapeutic modalities.
Background
Amy Rhoden Smith began her career as an Undergraduate Research Assistant at the College of Charleston from 2006 to 2008. She then transitioned to The University of Texas at Austin as a Graduate Research Assistant from 2008 to 2013. Following her academic pursuits, she worked at Moderna Therapeutics as a Scientist in Bio-organic/RNA Chemistry for one year in 2014-2015, before joining Intellia Therapeutics, Inc. where she held positions as Senior Scientist and Principal Scientist until 2018.
Achievements
Throughout her career, Amy Rhoden Smith has demonstrated a proven ability to build and lead cross-functional teams. She has successfully initiated and driven multiple projects in the field of gene therapy and therapeutics. Her deep expertise in translating early ideas into next-generation therapeutics has been a significant asset in her roles across various organizations, including her current position at Precision BioSciences.